Neon Therapeutics and Apexigen enter melanoma trial collaboration
Neon Therapeutics Inc. and Apexigen Inc. signed a clinical trial collaboration to evaluate the combination of Neon’s neoantigen vaccine NEOPV01 with Apexigen’s antibody APX005M in a Phase Ib trial for metastatic melanoma.
- Intra-Biotech Deal
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.